Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Ovelle is a research-first startup advancing IVG by engineering epigenetic reprogramming in human iPSCs to produce eggs. You will lead genome-wide epigenetic profiling, build analytical toolkits, and develop strategies to master reprogramming beyond current protocols.
The role offers collaborative, cutting-edge research with a strong emphasis on reproducibility and publication. This position focuses on pushing the frontier of oogenesis, driving developmental competence of eggs, and contributing
Ovelle is revolutionizing fertility treatment through human in vitro oogenesis—producing eggs from somatic cells. We have developed technology to create the cell types of the ovary from human induced pluripotent stem cells (iPSCs) by manipulating expression of transcription factors and RNA-binding proteins. Notably, we are the first company to produce meiotic oocyte-like cells from human iPSCs. This is an important step towards in vitro oogenesis because activating meiosis has been a key challenge in the field. We are incorporating these meiotic oocyte‑like cells into ovarian organoids to create synthetic ovaries capable of producing eggs. By innovating egg production, we aim to make fertility treatments more accessible and affordable. If we are successful, it will mark a paradigm shift in treatments for infertility, and offer a new path to parenthood for millions of people around the world. Come help us build the exciting future we all want to live in.
We seek an Epigenetic Reprogramming Scientist to lead our effort to control the genome-wide epigenetic reprogramming that happens during oogenesis. You will build the biological and analytical toolkit for measuring, benchmarking, and controlling all aspects of epigenetics (including DNA methylation, histone modifications, chromatin accessibility, and 3D genome organization) to drive oogenesis in vitro and ensure consistently high developmental competence of the resulting eggs. This role offers a rare chance to own the hardest, most consequential step in the IVG problem, in a field with immense potential to impact global health and happiness.
Ovelle is a research‑first startup where scientists work together on only one deep and important problem: IVG. We operate like a fast, efficient academic lab without constraints. We’re committed to sharing our work with the scientific community and welcome collaborations with academic researchers.
We recently closed an oversubscribed funding round led by a top‑tier VC firm, giving us 3–4 years of runway at our current pace.